Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vireo GrowthVREOF +0.20%44 Debt-to-Equity is 1.37 as of Mar. 2026, which is 121% above its 10-year median of 0.62. GuruFocus rates VREOF with a GF Score™ of 44/100 and a GF Value™ of $7.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, Vireo Growth ranks worse than 91.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vireo Growth's Debt-to-Equity or its related term are showing as below:
VREOF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -33.64 Med: 0.62 Max: 40.53
Current: 1.37
During the past 13 years, the highest Debt-to-Equity Ratio of Vireo Growth was 40.53. The lowest was -33.64. And the median was 0.62.
VREOF's Debt-to-Equity is ranked worse than 91.27% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs VREOF: 1.37
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vireo Growth Debt-to-Equity Related Terms
Vireo Growth Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a Debt-to-Equity of 1.37 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vireo Growth and its competitors. This is 121% above median its historical median of 0.62. According to the industry distribution chart, Vireo Growth ranks #742 out of 813 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Vireo Growth's Debt-to-Equity too high?
Vireo Growth's current Debt-to-Equity of 1.37 is 121% above median its 10-year median of 0.62. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Vireo Growth's value of 1.37 is 407.4% above this industry median. Based on the distribution chart, Vireo Growth ranks #742 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #742 out of 813 companies for Debt-to-Equity. This places Vireo Growth in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Vireo Growth's value of 1.37 is 407.4% above this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 0.27, Vireo Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Debt-to-Equity of 1.37 is 407.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Debt-to-Equity is 1.37, which is 121% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.63, compared to a current price of $9.78 — trading 28.2% above its estimated fair value. The current Debt-to-Equity is 1.37, which is 121% above median its 10-year median of 0.62 and 407.4% above the Drug Manufacturers industry median of 0.27. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vireo Growth (VREOF), the current Debt-to-Equity is 1.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $9.78 is trading 28.2% above its estimated GF Value™ of $7.63.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for VREOF:
Debt-to-Equity: 1.37 (121% above median its 10-year median of 0.62)
GF Value™: $7.63 vs. price of $9.78 (28.2% above fair value)
Industry Position: 407.4% above the Drug Manufacturers median (#742 of 813)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for VREOF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
